Categories: News

Correction: Form 8.3 – AXA INVESTMENT MANAGERS: dealings

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) AXA Investment Managers S.A.
Company dealt in Applegreen PLC
Class of relevant security to which the dealings being disclosed relate (Note 2) € 0.01 ordinary shares
Date of dealing 14th January 2021
  1. INTERESTS AND SHORT POSITIONS
     
  2. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
  Long Short
  Number   (%) Number   (%)
(1) Relevant securities 2,643,750    (2.19%)  
(2) Derivatives (other than options)    
(3) Options and agreements to purchase/sell    
Total 2,643,750    (2.19%)  

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
  Number   (%) Number   (%)
(1) Relevant securities    
 

(2) Derivatives (other than options)

   
 

(3) Options and agreements to purchase/sell

   
Total    


Ap20

  1. DEALINGS (Note 4)
     
  2. Purchases and sales
 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Sale 200,000 GBP 5.04

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

       

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
             

(ii)      Exercising

Product name,

e.g. call option

Number of securities Exercise price per unit (Note 5)
     

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details Price per unit

(if applicable) (Note 5)

     


Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

                        None

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure 15th January 2021
Contact name Victoria Warmé
Telephone number +33 (0) 1 44 45 83 60
If a connected EFM, name of offeree/offeror with which connected  
If a connected EFM, state nature of connection (Note 10)  

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) AXA Investment Managers S.A.
Company dealt in Applegreen PLC
Class of relevant security to which the dealings being disclosed relate (Note 2) € 0.01 ordinary shares
Date of dealing 14th January 2021
  1. INTERESTS AND SHORT POSITIONS
     
  2. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
  Long Short
  Number   (%) Number   (%)
(1) Relevant securities 2,643,750    (2.19%)  
(2) Derivatives (other than options)    
(3) Options and agreements to purchase/sell    
Total 2,643,750    (2.19%)  

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
  Number   (%) Number   (%)
(1) Relevant securities    
 

(2) Derivatives (other than options)

   
 

(3) Options and agreements to purchase/sell

   
Total    

Ap20

  1. DEALINGS (Note 4)
     
  2. Purchases and sales
 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Sale 2,000,000 GBP 5.04

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

       

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
             

(ii)      Exercising

Product name,

e.g. call option

Number of securities Exercise price per unit (Note 5)
     

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details Price per unit

(if applicable) (Note 5)

     

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

                        None

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure 18th January 2021
Contact name Victoria Warmé
Telephone number +33 (0) 1 44 45 83 60
If a connected EFM, name of offeree/offeror with which connected  
If a connected EFM, state nature of connection (Note 10)  

Staff

Recent Posts

NashBio Announces New Suite of Strategic Data Solutions to Accelerate Life Science Research and Development

These products address critical challenges in accessing and analyzing real-world data while advancing precision medicine…

15 minutes ago

VSee Health Secures Major Contract with Leading Florida Health System to Deliver Home Health and TeleNursing

Driving Healthcare Innovation and Growth Across Hospitals and CommunitiesSAN JOSE, Calif.--(BUSINESS WIRE)--VSee Health, Inc. (Nasdaq:…

18 minutes ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Current Co-Chairman of the Board will now also serve as Chief Executive OfficerMIAMI--(BUSINESS WIRE)--Pulse Biosciences,…

19 minutes ago

Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Recognition underscores BMS' continued commitment to innovation, responsibility, ESG impact and growthPRINCETON, NJ / ACCESSWIRE…

23 minutes ago

PharmD On Demand + 340B

Unlocking Significant Savings for Rural Hospitals WATKINSVILLE, GA / ACCESSWIRE / January 10, 2025 /…

23 minutes ago

RAAPID Raises Series A from M12, Microsoft’s Venture Fund to Scale Next-Generation Healthcare Risk Adjustment

Company reports 300% revenue growth in 2024 and advances partnerships with nation's leading health systems…

3 hours ago